BioPharm America™ 2016: ContraVir conducting Phase II studies for combination therapy in HBV

September 27, 2016
ContraVir CEO James Sapirstein talked with Informa Pharma Intelligence at BioPharm America 2016 about his company's plans to improve on current therapies for hepatitis B (HBV) with lipid formulation of Viread, a standard-of-care drug in both HBV and HIV. Lead candidate CMX157 is in a pair of Phase II studies and ContraVir hopes that the drug will become a backbone agent for combination therapy in HBV, similar to the combination regimens that have revolutionized treatment for HIV and hepatitis C. Sapirstein also talked about ContraVir's acquisition this past June of Ciclofilin Pharmaceuticals, which brought the company a preclinical drug candidate that could provide an immunomodulatory complement to CMX157.
Previous Video
BPA16 Interview Troy Wilson, Kura Oncology 1
BPA16 Interview Troy Wilson, Kura Oncology 1

Next Video
BioPharm America™ 2016: Cloud computing is the secret to Cloud Pharmaceuticals' drug discovery
BioPharm America™ 2016: Cloud computing is the secret to Cloud Pharmaceuticals' drug discovery

Cloud Pharmaceuticals COO Don Van Dyke speaks with Informa Pharma Intelligence at BioPharm America 2016 abo...